Jim Fong
Corporate Officer/Principal bei CTI BIOPHARMA CORP.
Profil
Jim Fong is currently the Chief Commercial Officer & Executive VP at CTI BioPharma Corp.
He previously worked as the Director-National Sales at CV Therapeutics, Inc. Mr. Fong completed his undergraduate degree at the University of California, Los Angeles.
Aktive Positionen von Jim Fong
| Unternehmen | Position | Beginn |
|---|---|---|
| CTI BIOPHARMA CORP. | Corporate Officer/Principal | 01.01.2008 |
Ehemalige bekannte Positionen von Jim Fong
| Unternehmen | Position | Ende |
|---|---|---|
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Vertrieb & Marketing | - |
Ausbildung von Jim Fong
| University of California, Los Angeles | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
CTI BioPharma Corp.
 CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA. | Health Technology |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Health Technology |
